Etrolizumab
Etrolizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target integrin alpha-7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
114 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 3 | — | 1 | — | 7 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | 3 | 3 | 7 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 2 | 1 | — | 3 |
| Premature obstetric labor | D007752 | — | O60 | — | — | — | 1 | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | 1 | — | 1 |
| Premature rupture fetal membranes | D005322 | — | O42 | — | — | — | 1 | — | 1 |
| Rupture | D012421 | — | — | — | — | — | 1 | — | 1 |
| Spontaneous rupture | D012422 | — | — | — | — | — | 1 | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
| Surgical wound infection | D013530 | — | — | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 11 | 15 | 4 | — | — | 25 |
| Burkitt lymphoma | D002051 | — | C83.7 | 2 | 6 | 4 | — | — | 11 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 2 | 2 | 6 | — | — | 10 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 2 | 2 | 3 | — | — | 7 |
| Ulcer | D014456 | MPATH_579 | — | 2 | 2 | 3 | — | — | 7 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | — | 1 | — | — | 5 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 2 | — | 1 | 4 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 2 | 1 | — | 1 | 4 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | 1 | 3 | 1 | — | — | 4 |
| Philadelphia chromosome | D010677 | — | — | — | 3 | 1 | — | — | 4 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 13 | 10 | — | — | — | 18 |
| Myelodysplastic syndromes | D009190 | — | D46 | 7 | 6 | — | — | — | 11 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 4 | — | — | — | 9 |
| Leukemia | D007938 | — | C95 | 5 | 6 | — | — | — | 8 |
| Multiple myeloma | D009101 | — | C90.0 | 4 | 2 | — | — | — | 6 |
| Hodgkin disease | D006689 | — | C81 | 5 | 3 | — | — | — | 6 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 3 | 5 | — | — | — | 6 |
| B-cell lymphoma | D016393 | — | — | 5 | 3 | — | — | — | 6 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 4 | 3 | — | — | — | 5 |
| Myeloid leukemia | D007951 | — | C92 | 4 | 4 | — | — | — | 5 |
Show 92 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 2 | — | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | — | — | — | — | 2 |
| Blast crisis | D001752 | — | — | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | — | — | — | — | 1 |
| Aplastic anemia | D000741 | — | D61.9 | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | — | — | — | 1 | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
| Snoring | D012913 | — | R06.83 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etrolizumab |
| INN | etrolizumab |
| Description | Etrolizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743015 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | I2A72G2V3J (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 598 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use